Literature DB >> 16430207

Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation.

Tetsuya Ishino1, Udaya Pillalamarri, Dominick Panarello, Madhushree Bhattacharya, Cecilia Urbina, Stephanie Horvat, Sanjay Sarkhel, Bradford Jameson, Irwin Chaiken.   

Abstract

The cyclic peptide AF17121 (VDECWRIIASHTWFCAEE) is a library-derived antagonist for human Interleukin-5 receptor alpha (IL5Ralpha). We have previously demonstrated that AF17121 mimics Interleukin-5 (IL5) by binding in a region of IL5Ralpha that overlaps the IL5 binding epitope. In the present study, to explore the functional importance of the amino acid residues of AF17121 required for effective binding to, and antagonism of, IL5Ralpha, each charged residue was subjected to site-directed mutagenesis and examined for IL5Ralpha interaction by using a surface plasmon resonance biosensor. One residue, Arg(6), was found to be essential for receptor antagonism; its replacement with either alanine or lysine completely abolished the interaction between AF17121 and IL5Ralpha. Other charged residues play modulatory roles. One class consists of the N-terminal acidic cluster (Asp(2) and Glu(3)) for which alanine replacement decreased the association rate. A second class consists of His(11) and the C-terminal acidic cluster (Glu(17) and Glu(18)) for which alanine replacement increased the dissociation rate. Binding model analysis of the mutants of the latter class of residues indicated the existence of conformational rearrangement during the interaction. On the basis of these results, we propose a model in which Arg(6) and N-terminal acidic residues drive the encounter complex, while Arg(6), His(11), and C-terminal acidic residues are involved in stabilizing the final complex. These data argue that the charged residues of AF17121 are utilized asymmetrically in the pathway of inhibitor-receptor complex formation to deactivate the receptor function. The results also help focus emerging models for the mechanism by which IL5 activates the IL5Ralpha-betac receptor system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430207      PMCID: PMC2538410          DOI: 10.1021/bi0518038

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  27 in total

1.  Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site.

Authors:  Cynthia S Dowd; Stephanie Leavitt; Gregory Babcock; Alexis P Godillot; Don Van Ryk; Gabriela A Canziani; Joseph Sodroski; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2002-06-04       Impact factor: 3.162

2.  Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration.

Authors:  T A Morton; D G Myszka; I M Chaiken
Journal:  Anal Biochem       Date:  1995-05-01       Impact factor: 3.365

3.  Mutagenesis in the C-terminal region of human interleukin 5 reveals a central patch for receptor alpha chain recognition.

Authors:  T Morton; J Li; R Cook; I Chaiken
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

4.  A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5.

Authors:  M V Milburn; A M Hassell; M H Lambert; S R Jordan; A E Proudfoot; P Graber; T N Wells
Journal:  Nature       Date:  1993-05-13       Impact factor: 49.962

5.  Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition.

Authors:  Tetsuya Ishino; Gianfranco Pasut; Jeffery Scibek; Irwin Chaiken
Journal:  J Biol Chem       Date:  2003-12-07       Impact factor: 5.157

6.  Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist.

Authors:  J Tavernier; T Tuypens; A Verhee; G Plaetinck; R Devos; J Van der Heyden; Y Guisez; C Oefner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins.

Authors:  K Johanson; E Appelbaum; M Doyle; P Hensley; B Zhao; S S Abdel-Meguid; P Young; R Cook; S Carr; R Matico
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

8.  Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor.

Authors:  T A Morton; D B Bennett; E R Appelbaum; D M Cusimano; K O Johanson; R E Matico; P R Young; M Doyle; I M Chaiken
Journal:  J Mol Recognit       Date:  1994-03       Impact factor: 2.137

9.  Identification of key charged residues of human interleukin-5 in receptor binding and cellular activation.

Authors:  P Graber; A E Proudfoot; F Talabot; A Bernard; M McKinnon; M Banks; D Fattah; R Solari; M C Peitsch; T N Wells
Journal:  J Biol Chem       Date:  1995-06-30       Impact factor: 5.157

10.  Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha.

Authors:  Piotr Ruchala; Gyorgyi Varadi; Tetsuya Ishino; Jeffery Scibek; Madhushree Bhattacharya; Cecilia Urbina; Donald Van Ryk; Iain Uings; Irwin Chaiken
Journal:  Biopolymers       Date:  2004-04-05       Impact factor: 2.505

View more
  9 in total

Review 1.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

Review 2.  Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon resonance (SPR) based biosensor study.

Authors:  James Beattie; Kirsten Phillips; John H Shand; Malgorzata Szymanowska; David J Flint; Gordon J Allan
Journal:  Mol Cell Biochem       Date:  2007-09-25       Impact factor: 3.396

3.  The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.

Authors:  Muddegowda Umashankara; Karyn McFadden; Isaac Zentner; Arne Schön; Srivats Rajagopal; Ferit Tuzer; Syna A Kuriakose; Mark Contarino; Judith Lalonde; Ernesto Freire; Irwin Chaiken
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

4.  Multivalent and flexible PEG-nitrilotriacetic acid derivatives for non-covalent protein pegylation.

Authors:  Anna Mero; Tetsuya Ishino; Irwin Chaiken; Francesco M Veronese; Gianfranco Pasut
Journal:  Pharm Res       Date:  2011-05-25       Impact factor: 4.200

5.  Non-natural peptide triazole antagonists of HIV-1 envelope gp120.

Authors:  Kantharaju Kamanna; Rachna Aneja; Caitlin Duffy; Pamela Kubinski; Diogo Rodrigo Moreira; Lauren D Bailey; Karyn McFadden; Arne Schön; Andrew Holmes; Ferit Tuzer; Mark Contarino; Ernesto Freire; Irwin M Chaiken
Journal:  ChemMedChem       Date:  2012-12-13       Impact factor: 3.466

6.  Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly.

Authors:  Tetsuya Ishino; Adrian E Harrington; Meirav Zaks-Zilberman; Jeffery J Scibek; Irwin Chaiken
Journal:  Cytokine       Date:  2008-02-21       Impact factor: 3.861

7.  Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.

Authors:  Hosahudya Gopi; M Umashankara; Vanessa Pirrone; Judith LaLonde; Navid Madani; Ferit Tuzer; Sabine Baxter; Isaac Zentner; Simon Cocklin; Navneet Jawanda; Shendra R Miller; Arne Schön; Jeffrey C Klein; Ernesto Freire; Fred C Krebs; Amos B Smith; Joseph Sodroski; Irwin Chaiken
Journal:  J Med Chem       Date:  2008-04-11       Impact factor: 7.446

8.  Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.

Authors:  Hosahudya Gopi; Simon Cocklin; Vanessa Pirrone; Karyn McFadden; Ferit Tuzer; Isaac Zentner; Sandya Ajith; Sabine Baxter; Navneet Jawanda; Fred C Krebs; Irwin M Chaiken
Journal:  J Mol Recognit       Date:  2009 Mar-Apr       Impact factor: 2.137

9.  Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.

Authors:  Bibek Parajuli; Kriti Acharya; Harry C Bach; Bijay Parajuli; Shiyu Zhang; Amos B Smith; Cameron F Abrams; Irwin Chaiken
Journal:  Biochem J       Date:  2018-03-09       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.